ADVERTISEMENT
News
Eye Drops Recalled
07/17/2020
The recall affects the following products, which were distributed throughout the United States:
- brimonidine tartrate ophthalmic solution 0.2%, 5-mL bottles (NDC 70069-231-01) from lots BRM11W9001, BRM11W9002, and BRM11W9003 (Exp. 11/20); BRM11W9004, BRM11W9005, and BRM11W9006 (Exp. 12/20); BRM11W9007, BRM11W9008, and BRM11W9009 (Exp. 3/21); BRM11W9010, BRM11W9011, BRM11W9012, and BRM11W9013 (Exp. 4/21); and BRM11W9014 and BRM11W9015 (Exp. 5/21);
- brimonidine tartrate ophthalmic solution 0.2%, 10-mL bottles (NDC 70069-232-01) from lots BRM12W9001 (Exp. 2020 [the FDA report does not specify the month]); BRM12W9002 and BRM12W9003 (Exp. 12/20); and BRM12W9004 (Exp. 4/21); and
- brimonidine tartrate ophthalmic solution 0.2%, 15-mL bottles (NDC 70069-233-01) from lots BRM13W9001, BRM13W9002, and BRM13W9003 (Exp. 12/20); and BRM13W9004 (Exp. 4/21).
Somerset Therapeutics voluntarily initiated the recall June 4, 2020. On July 7, 2020, the FDA designated it Class III, suggesting use of the affected product is not likely to cause harm.
Brimonidine tartrate is a prescription medication used to lower intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
—Jolynn Tumolo